Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical company, has reported its financial results for the first quarter ended March 31, 2025. The company experienced a net loss of $14.3 million during this period, a significant increase from the net loss of $7.9 million recorded in the same quarter of 2024. The increase in net loss is primarily attributed to heightened research and development expenses, which rose to $9.4 million from $6.8 million in the prior year. As of March 31, 2025, Belite Bio had $157.4 million in cash, liquidity funds, time deposits, and U.S. treasury bills. Income during the quarter was mainly derived from accrued interest from time deposits and U.S. treasury bills. In terms of business operations, the company is advancing the clinical development of Tinlarebant, having achieved a favorable interim analysis of its Phase 3 DRAGON trial. The trial is expected to be completed by the end of 2025. Additionally, Belite Bio completed a registered direct offering in February 2025, raising gross proceeds of $15 million, with the potential for an additional $15 million from the exercise of five-year warrants issued in the offering.